Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Non-metastatic
•
premenopausal
•
mammaprint
•
pt3
Would a low genomic Mammaprint score deter you from offering adjuvant chemotherapy to a premenopausal woman with pT3N0 breast cancer?
Related Questions
How would you manage a young premenopausal woman with hormone receptor-positive micrometastatic breast cancer in two axillary lymph nodes, but with only DCIS on breast surgical pathology?
How do you approach early-stage breast cancer patients who are asking for ctDNA or tumor marker surveillance (or previously receiving these with another provider) when these are not part of the NCCN or ASCO guidelines?
When do you recommend preoperative chemotherapy or hormonal therapy for ER+ breast cancer?
Would you offer adjuvant chemotherapy for triple negative invasive papillary carcinoma of breast?
What recommendations would you make for a patient on long-term phenytoin due to epilepsy with a newly diagnosed breast cancer requiring doxorubicin as part of her chemotherapy?
Do you hold endocrine therapy during adjuvant breast radiotherapy?
How do you assess and counsel women with chronic post lumpectomy or mastectomy pain ?
How would you treat a T2N1 ER 90%, PR 10%, HER-2 negative breast cancer in premenopausal women with a tumor appearing abutting the pectoralis fascia with loss of fat plane, with a concern for a positive surgical margin?
Would you offer adjuvant AC + pembrolizumab for a triple negative breast cancer patient whose tumor progressed on carboplatin + paclitaxel + pembrolizumab on KEYNOTE-522 and required urgent surgery (ypT3 ypN0)?
Would you consider offering adjuvant Olaparib to a patient with early stage triple negative breast cancer, cT3N0, ypT1aN0, with BRCA VUS who has residual disease after neoadjuvant KEYNOTE-522 regimen?
